Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer

• Status: Withdrawn
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Losartan potassium may be effective in treating pulmonary fibrosis caused by radiation therapy in patients with non-small cell lung cancer.

PURPOSE: This clinical trial is studying losartan to see how well it works in treating pulmonary fibrosis caused by radiation therapy in patients with stage I, stage II, or stage III non-small cell lung cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of South Florida
• Collaborator: National Cancer Institute (NCI)
• Treatments: Losartan

Criteria

INCLUSION CRITERIA:

• At least 18 years of age or older

• Diagnosed with non-small cell lung cancer stage I, II, IIIa, or IIIb

• Diagnosis of radiation-induced pulmonary fibrosis (as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events [CTCAE] V3.0 Grade I to Grade III) and within 2 years of the last radiation therapy treatment

EXCLUSION CRITERIA:

• Patients with a pneumonectomy

• Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker

• Use of an angiotensin II receptor blocker currently or within 6 months of study entry which include: losartan, valsartan, irbesartan, candesartan, cilexetil, eprosartan mesylate, and telmisartan

• Bilateral renal artery stenosis, hereditary or idiopathic angioedema, or uncontrolled hypotension

• Patients taking lithium

• Currently smoking or smoked within 6 months of study entry

• Pregnant, intending to become pregnant or breastfeeding

• Baseline systolic blood pressure < 100 mmHg

• History of lung transplant

• History of kidney failure or liver disease

• Inability to attend clinic visits